trial

Effects of RG1068 (Secretin) on Information Processing in Schizophrenia

NCTId NCT00235274
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 30
Sponsored by Indiana University
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
30
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2005-11
Primary completion
—
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Subcutaneous Secretin

Sponsors

Indiana UniversityLead Sponsor
Shekhar, Anantha M.D., Ph.D.Collaborator
Repligen CorporationCollaborator

Investigators

1
Anantha Shekhar, MD, PhDPrincipal Investigator

Sites

1 total
Indianapolis, United States

Facts & assertions

3 sourced
Enrollment
30
Phase
PHASE2
Status
COMPLETED
relationships
The graph out of here
drug
Subcutaneous Secretin
drug
lead_sponsor
Indiana University
company
collaborator
Shekhar, Anantha M.D., Ph.D.
company
Repligen Corporation
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Anantha Shekhar, MD, PhD
person